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Abstract
Background: p63 is a member of the p53 family that has been implicated in maintenance of epithelial stem cell
compartments. Previous studies demonstrated that p63 is downregulated in muscle-invasive bladder cancers, but the
relationship between p63 expression and survival is not clear.
Methodology/Principal Findings: We used real-time PCR to characterize p63 expression and several genes implicated in
epithelial-to-mesenchymal transition (EMT) in human bladder cancer cell lines (n=15) and primary tumors (n=101). We
correlated tumor marker expression with stage, disease-specific (DSS), and overall survival (OS). Expression of E-cadherin and
p63 correlated directly with one another and inversely with expression of the mesenchymal markers Zeb-1, Zeb-2, and
vimentin. Non-muscle-invasive (Ta and T1) bladder cancers uniformly expressed high levels of E-cadherin and p63 and low
levels of the mesenchymal markers. Interestingly, a subset of muscle-invasive (T2–T4) tumors maintained high levels of E-
cadherin and p63 expression. As expected, there was a strongly significant correlation between EMT marker expression and
muscle invasion (p,0.0001). However, OS was shorter in patients with muscle-invasive tumors that retained p63 (p=0.007).
Conclusions/Significance: Our data confirm that molecular markers of EMT are elevated in muscle-invasive bladder cancers,
but interestingly, retention of the ‘‘epithelial’’ marker p63 in muscle-invasive tumors is associated with a worse outcome.
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Introduction
Bladder cancers develop along two ‘‘tracks’’ producing tumors
with very different clinical characteristics [1]. One leads to the
formation of papillary tumors with high recurrence rates that
rarely metastasize or cause death, whereas the other leads to the
development of non-papillary, muscle-invasive tumors, of which a
subset progresses rapidly and is fatal. At present it is impossible to
prospectively identify the lethal muscle-invasive tumors; however,
accumulating evidence suggests that molecular reprogramming
characteristic of a developmental process known as epithelial-to-
mesenchymal transition (EMT) is involved. Muscle-invasive
cancers are characterized by downregulation of E-cadherin and
p63, two ‘‘epithelial’’ markers uniformly expressed in normal
urothelium and in non muscle-invasive cancers [2–5]. These
changes are accompanied by upregulation of mesenchymal
markers Zeb-1, Zeb-2, vimentin, and MMP9, leading to increased
invasion and migration. A role for EMT in driving bladder cancer
progression and metastases is consistent with a large body of
evidence emerging in other solid tumors, particularly breast cancer
[6–8]. Furthermore, enforced expression of EMT regulators can
cause changes reminiscent of those observed in cancer stem cells
[8–10]. Because cancer stem cells appear generally to be resistant
to conventional chemotherapy, the link between EMT and
‘‘stemness’’ provides additional support for the idea that EMT
contributes to lethality.
We initiated the present study to directly test the hypothesis that
EMT markers could identify the subset of muscle-invasive tumors
displaying aggressive clinical behavior. In human bladder cancer
cell lines, we observed a direct correlation between E-cadherin and
p63 expression, and an inverse correlation between these markers
and Zeb-1, Zeb-2, and vimentin, indicating they cluster into
unique ‘‘epithelial’’ and ‘‘mesenchymal’’ subsets. Our data
confirm that mesenchymal markers (Zeb-1, Zeb-2, MMPs, and
vimentin) are expressed almost exclusively by muscle-invasive
tumors [11,12], the subset of bladder cancer with worse outcome.
Interestingly, our data also demonstrate that within this muscle-
invasive subset, tumors retaining p63 (which appears to be an
‘‘epithelial’’ marker), display significantly worse survival than those
muscle-invasive tumors displaying a more typical ‘‘mesenchymal’’
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p63 and poor survival outcome.
Results
Expression of EMT markers in published gene expression
datasets
We first examined the expression of EMT markers in two
publicly available gene expression profiling datasets [13,14]. In
both, unsupervised hierarchical clustering distinguished superficial
from muscle-invasive disease [13,14]. Superficial tumors expressed
higher levels of ‘‘epithelial’’ marker E-cadherin than muscle-
invasive tumors; conversely, muscle-invasive tumors expressed
higher levels of ‘‘mesenchymal’’ markers (Figure 1A-B).
Relationships among EMT markers in human bladder
cancer cell lines
We next measured the expression of EMT markers in 15
bladder cancer cell lines by quantitative real-time PCR. Results
suggested the existence of 2 dichotomous subsets of tumors,
one displaying an ‘‘epithelial’’ pattern characterized by expres-
sion of E-cadherin and p63; the other characterized by expression
of ‘‘mesenchymal’’ markers Zeb-1, Zeb-2, and vimentin
(Figure 2A–B). Quantification of both p63 mRNA (Figure 2B)
and protein (data not shown) levels demonstrated it was expressed
exclusively by the E-cadherin-positive, ‘‘epithelial’’ cell lines, and
that expression of the DN-p63 isoforms exceeded expression of
the TA-p63 isoforms by several orders of magnitude (Figure 2B).
Contrary to our expectations, MMP2 and MMP9 levels were not
closely associated with EMT in our cell lines (Figure 2C);
however, the small number of cell lines for which the MMPs were
elevated impacts the significance of this observation. Importantly,
previous studies concluded that ‘‘mesenchymal’’ bladder cancer
cells are as a group highly invasive and resistant to radiation and
EGFR-directed therapy [11,12,15–17], suggesting they might
possess unfavorable biological characteristics.
EMT marker expression in a new set bladder tumors
We then measured the gene expression of EMT markers by
RT-PCR in primary bladder cancers (n=101, Table 1).
Consistent with the public data (Figure 1) and other reports
[11,12], real time PCR data revealed that superficial tumors
expressed higher levels of epithelial markers E-cadherin and p63,
whereas muscle-invasive tumors expressed higher levels of
mesenchymal markers (vimentin, Zeb1, Zeb2, MMP2,
MMP9)(Figure 3 A and B). As shown in Figure 3, superficial
Figure 1. EMT marker expression in bladder cancers including primary tissue. A & B: All EMT marker genes with significant differences in
expression (P,0.001) in 2 independent publicly available datasets. An in-house cDNA microarray with 10368 probes was used in A [13]. The HU-133A
Affymetrix platform was used in B [14].
doi:10.1371/journal.pone.0030206.g001
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p63 [3,4,18–23] than did muscle-invasive tumors (p-val-
ue,0.0001, Figure S1A). Similarly to our cell line data, DN-
p63 was the major isoform of p63 present in primary tumor tissue
(Figure 3C). Conversely, muscle-invasive tumors more frequently
expressed the mesenchymal markers (Zeb-1, Zeb-2, vimentin)
Figure 2. Differential expression of EMT markers in bladder cancer cell lines. (A) mRNA expression of E-cadherin, Zeb-1, Zeb-2 and
vimentin were measured by quantitative real-time PCR. An inverse correlation between E-cadherin and Zeb-1/Zeb2 was observed across the cell lines.
(B) mRNA expression of total p63, TAp63 and DN-p63 isoforms were measured by isoform specific primers. (C) Relative mRNA expression of MMP2
and MMP9 in bladder cancer cells. Data shown are mean 6 SEM from triplicate samples.
doi:10.1371/journal.pone.0030206.g002
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S1B). As we had observed in cell lines, expression of E-cadherin
was directly associated with expression of p63 (Spearman’s
correlation coefficient rho=0.32, p=0.0028) and inversely with
expression of Zeb-1 (rho=20.37, p,0.0001), Zeb-2 (rho=
20.48, p,0.0001), and vimentin (rho=20.49, p,0.0001). On
the other hand, although MMP2 and MMP9 were also expressed
at higher levels in the muscle-invasive tumors compared to
superficial tumors (both p-values,0.0001, Figure S1C), we did
not observe as strong correlations between expression of MMP2
and MMP9 and expression of p63 in either the overall set of
tumors (Spearman’s correlation rho=20.17, p=0.08, between
p63 and MMP9, and rho=20.24, p=0.01 between p63 and
MMP2), or in the sub-group of muscle-invasive patients
(rho=20.15, p=0.21, between p63 and MMP9, and
rho=20.23, p=0.065 between p63 and MMP2). However, a
strong inverse correlation between E-cadherin and MMP9, and
MMP2 was still maintained (rho=20.46, p,0.001 with MMP9,
rho=20.38, p,0.001 with MMP2) in the overall group, and the
same associations were observed in muscle-invasive patients
(rho=20.45, p,0.001 with MMP9; rho=20.39, p=0.002 with
MMP2).
Higher p63 and MMP9 are associated with adverse OS in
patients with muscle-invasive disease
Finally, we correlated EMT marker expression as measured by
RT-PCR with survival. Since, as a group, patients with superficial
tumors survive longer than those with muscle-invasive tumors,
expression of an EMT phenotype characterized by loss of E-
cadherin and p63 was associated with a poor prognosis, largely as
a result of the ability to stratify patients between superficial and
muscle-invasive disease (data not shown). However, when confined
to the muscle-invasive subset of tumors, we found that retention of
p63 expression was associated with adverse outcome (Figure 4A–
B). The cutoff point for elevated p63.1.60 was obtained using
regression tree analysis. Specifically, elevated p63 was associated
with a significantly worse median OS of 8 months (95%
confidence interval of 4, 140 months), whereas patients with
lower levels of p63 had an improved median OS of 27 months
(95% CI of 17, 85 months, log-rank p=0.007). Analyses of the
results for DSS outcomes were similar to those for OS outcome.
Elevated p63 was associated with a median DSS of 8 months with
a 95% confidence interval of (19, 140) months, whereas patients
with lower levels of p63 had an improved median DSS of 41
months (95% CI: 19, 140+months, log-rank p-value=0.004).
Even in this muscle-invasive group, maintenance of p63 correlated
directly with the expression of epithelial markers (E-cadherin
rho=0.34, p=0.006), and inversely with mesenchymal markers
(vimentin: rho=20.35, p=0.0047; zeb-1: rho=20.36, p=0.003;
and zeb-2: rho=20.39, p=0.0014; respectively). Interestingly,
retention of p63 in patients classified as having T1 tumors was also
associated with significantly adverse survival outcome. Patients
with T1 disease with higher levels of p63 had a median survival of
58 months, whereas there were no disease-related deaths in
patients with lower levels of p63 in this subset (data not shown).
In a previous study we showed that a low E-cadherin/MMP9
ratio was also associated with an adverse survival outcome.
Therefore, we also assessed the relationship between MMP9
expression and OS in this cohort (Figure 4C and D). Consistent
with the previous data, high level expression of MMP9 was
associated with shorter OS (median OS 10.2 months, 95% CI 4.9,
26.6) as compared to those tumors expressing lower amounts of
MMP9 (median OS 35.4 months, 95% CI 19.3, 107.9, p=0.003,
Figure 4C). Likewise the median DSS was shorter with high-level
expression of MMP9 (median DSS 10.3 months, 95% CI 4.9,
140+ months) and compared to those expressing lower amounts of
MMP9 (median DSS.140, 95% CI 19.3, 140+ months, p=0.01,
Figure 4D).
We also confirmed the association between elevated p63 and
poor survival in muscle-invasive urothelial cancer using an
independent gene-expression dataset (GEO Accession number
GSE13507 [24])Using regression-tree analysis, the cut-off point for
p63 elevation was obtained. Elevated p63 was associated with a
significantly worse OS and DSS (log-rank p=0.012 and 0.002,
respectively, Figure S2). Additional attempts at tissue confirmation
using immunohistochemistry in a muscle-invasive bladder cancer
tissue microarray were inconclusive, largely as a result of lack of
specificity of the commercially available 4A4 antibody for DN-p63,
a finding also confirmed by an outside group [25].
p63 and MMP9 are independent predictors of OS
A multivariate Cox regression model was used to assess
simultaneously the effect of expression of two or more EMT
markers by RT-PCR and disease stage on OS. It is not surprising
that disease stage was a statistically significant predictor of OS
(HR=2.15 invasive vs. superficial, p=0.05). Interestingly, both
continuous p63 and MMP9 were independent predictors of OS
Table 1. Clinicopathologic characteristics of bladder tumor
samples for RT-PCR, N=101.
Number %
Age at tissue collection
Median 64
Range 40–92
Gender
Female 27 (27%)
Male 74 (73%)
Race
Caucasian 82 (81%)
African American 11 (11%)
Hispanic 6 (6%)
Asian 1 (1%)
Arabic 1 (1%)
Histology
TCC 74 (73%)
Mixed* 27 (27%)
TCC with squamous 17 (17%)
TCC with micropapillary 3 (3%)
TCC with sarcomatoid 3 (3%)
TCC with small cell 2 (2%)
TCC with adenocarcinoma 1 (1%)
TCC with lymphoepithelioma 1 (1%)
Stage
TaN0M0 14 (14%)
T1N0M0 20 (20%)
T2N0M0 6 (6%)
T3-4aN0M0 23 (22%)
T4b or N+ or M+ 38 (38%)
*All cases of mixed histology were present in the invasive group except for one
case of micropapillary in the non-invasive group for the RT-PCR.
doi:10.1371/journal.pone.0030206.t001
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30206Figure 3. Expression of EMT markers in primary bladder tumors. (A) Expression of core E-cadherin-related EMT markers (E-cadherin, p63,
Zeb-1, and Zeb-2) in 101 primary bladder tumors was assessed by quantitative real-time PCR. (B) Expression of MMP2, MMP9, and vimentin. (C)
Expression of TAp63 and DN-p63 in a representative subset of the samples. All samples in each figure are shown in the same order.
doi:10.1371/journal.pone.0030206.g003
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30206Figure 4. Kaplan-meier overall survival (OS) and disease-specific survival (DSS) curves based upon RT-PCR data for p63 and MMP9
in the subset of invasive tumors. All p-values provided are 2-sided, using the log-rank test. A: Elevated p63 was associated with adverse outcome
in patients with muscle-invasive cancer (median OS 8 months, 95% confidence interval 4, 140 months), as compare to lower expression of p63
(median OS 27 months, 95% CI of 17, 85 months) log-rank p=0.007. B: Elevated p63 was associated with adverse DSS in patients with muscle-invasive
cancer (median DSS 8 months, 95% CI 19, 140), whereas patients with lower levels of p63 had an improved median DSS of 41 months (95% CI 19,
140+ months, log-rank p=0.004). C: Elevated MMP9 was associated with adverse outcome (median OS 10.2 months, 95% CI i4.9, 26.6) as compared to
lower MMP9 (median OS 35.4 months, 95% CI 19.3, 107.9, p=0.003). D: Elevated MMP9 was associated with adverse DSS (median 10.3 months, 95%
CI: 4.9, 140+) as compared to lower MMP9 (median DSS.140, 95% CI: 19.3, 140+ months, p=0.01). E (OS) and F (DSS): Using a multivariate Cox
regression model, p63 and MMP9 were independent predictors for adverse outcome in muscle-invasive disease. Patients were assigned 1 point each
for either elevated p63 or MMP9 (0=neither elevated, 1=either elevated, 2=both elevated). Worst survival was observed when both markers were
elevated, and best when neither was elevated (median OS for 0, 1, or 2: .=69, 10 months, and 8 months, with a 5-year OS or 55%, 8%, and 0%
respectively).
doi:10.1371/journal.pone.0030206.g004
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p=.013) in addition to disease stage among all 101 patients. Other
marker expressions were not associated with OS outcome in the
multivariate model. Despite including other tumor characteristics,
including presence/absence of squamous histology, disease stage,
and age at diagnosis in the multivariate regression model, both p63
and the log of MMP9 remained as independent predictors of OS
(p63: HR=1.54, p=0.017; log-MMP9: HR=1.26, p=0.011).
Both p63 and the log transformation of MMP9 were also
independent predictors of DSS (p63: HR=2.04 for p63,
p=0.0006, log MMP9: HR=1.31, p=.006) in addition to disease
stage among all 101 patients. Including presence/absence of
squamous histology, disease stage, and age at diagnosis in the
multivariate regression model, both p63 and the log of MMP9
remained as independent predictors of DSS (p63: HR=1.63,
p=0.022; log-MMP9: HR=1.35, p=0.003). When we restricted
our multivariate marker analyses to the muscle-invasive tumors
(n=67, from the 101 samples used in RT-PCR), the same trend
but slightly increased hazard ratios for OS with both p63 and
MMP9 was observed (p63: HR=2.17, p=0.0003; log-MMP9:
HR=1.31, p=0.007), suggesting that both p63 and MMP9 are
independent predictors for adverse survival in muscle-invasive
disease. The same trend was also observed with slightly increased
hazard ratios for DSS (p63: HR=2.40, p=0.0018; log-MMP9:
HR=1.37, p=0.003) as compared to OS. Assigning patients 1
point each for either elevated expression of p63 or MMP9
(0=neither elevated, 1=either elevated, 2=both elevated),
stratified survival with the worst survival when both were elevated
(Figure 4E and F), and the best survival when neither was elevated
(median OS for 0, 1, or 2: .=69, 10 months, and 8 months, with
a 5-year OS of 55%, 8% and 0% respectively). Proportional
hazards assumptions for each risk factor is satisfied in the
regression model for either 67 muscle-invasive patients, or 101
patients with primary bladder cancer.
Discussion
Previous studies concluded that loss of p63 is associated with
shorter survival in patients with bladder cancer [3,20]. In contrast,
our results suggest that maintenance of p63 expression is
associated with adverse outcomes in patients with muscle-invasive
bladder cancer. On the surface our results appear to contradict
these other studies. However, we suspect this apparent discrepancy
is due in part to the inclusion of superficial cancers displaying
uniformly good survival characteristics in the earlier analyses as
opposed to our current focus on their impact in muscle-invasive
disease. As a group, the most superficial bladder cancers have
excellent long-term survival (near 100%), and uniformly express
high levels of E-cadherin and p63. On the other hand, loss of p63
is restricted to a subset of the muscle-invasive tumors, and muscle-
invasive disease is typically associated with worse clinical outcomes
as compared to superficial, non-invasive cancer. Therefore,
inclusion of superficial tumors uniformly displaying an ‘‘epithelial’’
phenotype could dilute out an adverse effect of an ‘‘epithelial’’
phenotype in the muscle-invasive cohort. In addition, the
commercial antibody (4A4) that is most commonly used to
measure p63 in tissue sections cannot distinguish the two major
p63 isoforms (TA and DN), so the relationship between DN p63
expression and poor outcome in muscle-invasive bladder cancers
could not be recognized in previous IHC-based studies that
employed this reagent [4,20]. We attempted to confirm our
mRNA-based results using the 4A4 on tissue microarrays and the
results were inconclusive (data not shown). Consistent with this
conclusion, while our manuscript was being prepared for
submission Cordon-Cardo’s group generated an anti-p63 antibody
that is specific for the DN isoforms and used it on an independent
cohort of muscle-invasive tumors to show that DN p63 protein
levels also identify a lethal subset of cancers, whereas their results
with the 4A4 antibody were inconclusive [25]. Ultimately
prospective studies will be required to rigorously test the clinical
significance of these findings.
Work performed over the past 5 years has renewed interest in
the role of EMT in cancer progression and metastasis. One
influential study demonstrated that isogenic metastatic variants of
a murine breast cancer cell line overexpressed the E-cadherin
repressor, Twist, and that elevated Twist expression was required
for metastasis [7]. Subsequent work demonstrated that enforced
Twist expression in normal mammary epithelial cells triggered
EMT and simultaneously upregulated expression of mammary
cancer stem cell markers [26]. Parallel studies by others have
reinforced the notion that EMT drives tumor progression,
metastasis, drug resistance, and a ‘‘stem-like’’ phenotype [10,27].
With respect to bladder cancers, recent studies implicated EMT in
disease progression, invasion/migration, and resistance to radia-
tion and targeted therapy [11,12,15–17]. With these observations
in mind, we expected that measuring EMT marker expression
would identify the most lethal subset of muscle-invasive bladder
cancers. Our results confirm that EMT markers were elevated in
muscle-invasive cancers. Strikingly, however, increased p63
expression was associated with adverse outcomes both in muscle-
invasive and in T1 tumors.
Several recent studies have shown that EMT and ‘‘stem-like’’
phenotype is regulated by micro RNAs (miR-205 and miR-200
family) [28–31]. miR-205 and the miR-200 family can maintain
the epithelial phenotype by suppressing the expression of
mesenchymal transcription factors (Zeb-1 and Sip1) and the
introduction of miR-205 and miR-200 into mesenchymal cells can
reverse mesenchymal cell morphology to an epithelial phenotype
[30]. Interestingly, we have recently discovered that DNp63
directly promotes miR205 expression (M. Tran, manuscript in
preparation), providing an explanation for the tight correlation
between expression of DNp63 and epithelial markers in bladder
cancer cell lines and primary tumors.
We are also investigating DNp63’s effects on bladder cancer cell
biology in order to better understand why its expression correlates
with poor patient survival. Although structurally similar to p53,
p63 is phylogenetically older than its cousin and displays much
higher inter-species conservation [32,33]. Furthermore, even
though p53 and p63 interact with similar DNA sequence motifs,
most p63 isoforms do not transactivate p53 target genes but rather
can function as dominant negatives suppressing p53-dependent
transactivation [33]. P63 is expressed at high levels in the basal
layers containing the normal stem cell compartments in many
different epithelial tissues, including the urothelium. Targeted
ablation of p63 expression disrupts normal bladder differentiation
in the mouse, leading to loss of the basal/suprabasal layer with
selective retention of so-called ‘‘umbrella’’ cells [34]. These
observations have led many investigators to propose that p63 is
essential for the maintenance of self-renewal and/or survival of
normal stem cells [35]. Thus, p63 expression in muscle-invasive
disease may be associated with both epithelial phenotype and
‘‘stemness’’[36-38]. However, cells within the normal urothelium
express TAp63 (not DNp63), which would be expected to have
very different effects on cell biology. Strikingly, our preliminary
studies indicate that stable knockdown of DNp63 in bladder cancer
cells causes strong inhibition of proliferation, effects that are
associated with downreguliation of c-Myc mRNA and protein
expression (L. Marquis et al, manuscript under revision),
p63 in Bladder Cancer
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as a negative prognostic marker is related to its effects on tumor
cell proliferation. Additional mechanistic studies are required to
define the relationships between the EMT phenotype, ‘‘stemness’’,
proliferation, drug sensitivity, and metastasis in preclinical models
and primary tumors.
Conclusions
Superficial (non muscle-invasive) tumors express higher levels of
the epithelial markers E-cadherin and p63, while muscle-invasive
tumors have higher expression of mesenchymal markers Zeb1,
Zeb2, Vimentin, MMP2 and MMP9. Nonetheless, there is a
subset of muscle-invasive cancer that has an adverse prognosis in
the setting of elevated p63 expression. This elevation in p63 is
associated with retained expression of E-cadherin and decreased
levels of mesenchymal markers including vimentin, Zeb1 and
Zeb2, suggesting that coupling between p63 expression and the
‘‘epithelial’’ phenotype remains present in a subset of muscle-
invasive cancers. MMP9 expression appears to be independent
from p63 in predicting adverse outcomes, suggesting regulation by
independent mechanisms. The molecular mechanisms driving
muscle invasion in tumors displaying an ‘‘epithelial’’ phenotype
and the role of EMT in chemotherapy responsiveness and
metastasis need to be more fully explored in future studies.
Materials and Methods
Using public gene expression datasets we determined whether
decreased expression of the ‘‘epithelial’’ marker E-cadherin and
increased expression of several ‘‘mesenchymal’’ markers (the E-
cadherin repressors Zeb-1, Zeb-2, and Twist, the matrix
metalloproteases MMP2 and MMP9, fibronectin, and vimentin)
was associated with progression to muscle-invasion. We then used
a panel of bladder cancer cell lines to determine whether
expression of ‘‘epithelial’’ and ‘‘mesenchymal’’ markers were
mutually exclusive displaying distinct ‘‘epithelial’’ and ‘‘mesen-
chymal’’ phenotypes. Using quantitative real-time PCR we tested
whether the relationship between EMT and muscle-invasive
disease was present in a new cohort of patients with bladder
cancer and correlated EMT marker expression with survival.
Analysis of EMT Markers in Public Gene Expression
Profiling Datasets
Two public human bladder cancer gene expression datasets
were used to analyze EMT markers. Data from Blavari et al and
Carbayo et al were downloaded from Gene Expression Omnius
(GEO Accession number GSE-1827 [13]) and the Journal of
Clinical Oncology [14], respectively. BRB ArrayTools version 4.2,
developed by NCI [39] was used to analyze the data [13,14]. To
select genes differentially expressed between the two different sub-
groups (superficial and muscle-invasive tumors), a class compar-
ison tool within BRB ArrayTools was used to calculate the
significance of the observations (ie: P,0.001 computed from two-
sample t-test with a false discovery rate (FDR) less than 0.1). To
observe patterns of EMT gene expression, each gene’s value,
adjusted to a mean of zero, was used for clustering with Cluster
and TreeView [40].
Cell lines
Cell lines were obtained from the MD Anderson Bladder
SPORE Tissue Bank, and their identities validated by DNA
fingerprinting using AmpFlSTRH IdentifilerH Amplification (Ap-
plied Biosystems, Foster City, CA) or AmpFlSTRH ProfilerH PCR
Amplification (Applied Biosystems), performed by the MD
Anderson Characterized Cell Line Core, or ourselves, respectively.
These fingerprints are available on the MD Anderson Bladder
SPORE website. Cell lines were cultured in modified Eagle’s
MEM supplemented with 10% fetal bovine serum, vitamins,
sodium pyruvate, L-glutamine, penicillin, streptomycin, and
nonessential amino acids at 37uCi n5 %C O 2 incubator.
Human specimens
Clinical outcomes data and patient samples for real-time PCR
were obtained for 101 patients from the MD Anderson
genitourinary cancers research database. Fresh frozen tissues were
obtained from our SPORE Tissue Core. Samples were collected
using macrodissection focusing on areas with at least 80% tumor
concentration. All patients had previously signed informed consent
allowing collection of their tissue and clinical data in our
genitourinary research database. An additional IRB approved
protocol was obtained for the specific analyses described in this
paper. All tissue samples were reviewed by a pathologist. Patients
were classified as muscle-invasive for tumor growth into the
muscularis propria; otherwise, they were classified as superficial
(non muscle-invasive). Total RNA from human specimens were
isolated using mirVana
TMmiRNA isolation kit (Ambion, Inc).
Real-time Reverse Transcriptase PCR analysis
EMT markers were analyzed by Taqman-based real-time PCR
(ABI PRISM 7500; Applied Biosystems). The comparative CT
method [41] was used to determine relative gene expression for
each target gene; the cyclophilin A gene was the internal control
used to normalize the amount of amplifiable RNA (Assay ID
numbers: E-cadherin; Hs00170423_m1, ZEB1; Hs00232783_m1,
ZEB2; Hs00207691_m1, Vimentin; Hs00185584_m1, MMP2;
Hs00234422_m1, MMP9; Hs00957562_m1 and Cyclophilin A;
Hs99999904_m1). Primers and fluorescent probes for p63
isoforms were designed by Primer Express 3.0 (Applied Biosys-
tems) with the following sequences: TAP63 forward primer 59-
TGCAGGACTCGGACCTGAGT-39, reverse primer 59- TGT-
TCAGGAGCCCCAGGTT-39, probes 59-ACCCCATGTGGC-
CAC-39; DN-p63 forward primer 59-GGAAAACAATGCCCA-
GACTCA-39, reverse primer 59- TGTTCAGGAGCCCCAG-
GTT-39, probes 59-TTTAGTGAGCCACAGTACAC-39. Primers
and probes for p63 isoforms were validated using standard curve
methods (data not shown).
Statistical Methods
Statistical analyses were based on information from 101
patients. The primary objectives were to examine correlations
between marker expression and disease stage, and to evaluate the
association between marker expression and overall survival (OS)
and disease-specific survival (DSS). Disease stage was stratified as
superficial (Ta or T1) or muscle-invasive (.=T2). Expression
values were compared between superficial and muscle-invasive
bladder cancer using the Wilcoxon rank sum test. Correlations
among expression of markers were quantified using Spearman’s
rho coefficients. The Kaplan-Meier estimate of survival distribu-
tion was displayed by the investigated biomarker expression
characterized as high and low (e.g. p63, MMP9), where the cutoff
point to define high and low was obtained from regression tree
analyses [42]. The log-rank test was used to compare survival
distributions between groups. The proportional hazards model
was used to assess the effects of multiple markers and tumor stage
on DSS and OS. We performed a logarithmic transformation of
the MMP9 expression values due to the skewedness of the data. All
p-values presented are 2-sided.
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Figure S1 EMT marker expression in primary bladder tumors
was measured by quantitative real-time PCR and stratified by
patient stage as superficial (Ta or T1), or muscle-invasive (.=T2).
A: The epithelial markers E-cadherin (CDH1) and p63 were
elevated in superficial tumors. B: The mesenchymal markers Zeb1,
Zeb2, and vimentin were expressed at higher levels in invasive as
compared to superficial tumors. C: MMP2 and MMP9 were also
expressed at higher levels in invasive tumors.
(TIF)
Figure S2 Elevated p63 was associated with worse prognosis in
an independent gene-expression dataset. A: Overall Survival.
Median OS not reached in low p63, and 13 months in high p63
(log-rank p=0.012). B. Disease-specific survival. Median DSS not
reached in low p63, and 15.1 months in high p63 (log-rank
p=0.002).
(DOCX)
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